UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  August 2, 2013

Viropro, Inc.
(Exact Name of Registrant as Specified in its Charter)

     
Nevada
333-06718
13-3124057
(State or other jurisdiction of incorporation)
(Commission File  Number)
(IRS Employer Identification No.)

     
69 Delaware Avenue
Suite 1212
Buffalo, NY
  
14202
(Address of principal executive offices)
  
(Zip Code)

Registrant's telephone number, including area code: (716) 855-3611

N/A

Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]     Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
 
[  ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
 
[  ]     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[  ]     Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

SEC 873  (5-06)
 
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 
 
 
 
 
Item 1.01 Entry into a Material Definitive Agreement

On August 2, 2013, Viropro engaged Torreya Emerging Markets to identify potential partnerships for Viropro’s biosimilars on a global basis. Torreya EM is a boutique advisory firm focused on mergers and acquisitions, licensing, and commercialization of pharmaceutical products and medical devices in emerging markets. Torreya EM has a global reach with offices in Princeton, Washington D.C., Mexico City, Rio de Janeiro, Johannesburg, Riyadh, and Hong Kong.


SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Date:  September  18, 2013

 

VIROPRO, INC.



/s/ Cynthia Ekberg Tsai

Cynthia Ekberg Tsai, Chair and CEO

 
 
 

Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Viropro (CE) Charts.
Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Viropro (CE) Charts.